Therapeutics formulated to target cancer stem cells: Is it in our future?
Open Access
- 1 January 2011
- journal article
- Published by Springer Nature in Cancer Cell International
- Vol. 11 (1) , 7
- https://doi.org/10.1186/1475-2867-11-7
Abstract
With the political, social and financial drives for cancer research, many advances have been made in the treatment of many different cancer types. For example, given the increase in awareness, early detection, and treatment of breast and prostate cancers, we have seen substantial increases in survival rates. Unfortunately there are some realms of cancer that have not seen these substantial advancements, largely due to their rapid progression and the inability to specifically target therapy.Keywords
This publication has 41 references indexed in Scilit:
- PTEN is a tumor suppressor in CML stem cells and BCR-ABL–induced leukemias in miceBlood, 2010
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2009
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449New England Journal of Medicine, 2009
- Hedgehog Signaling Is Dispensable for Adult Murine Hematopoietic Stem Cell Function and HematopoiesisCell Stem Cell, 2009
- PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like CellsCell Stem Cell, 2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)BMC Cancer, 2008
- CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyBlood, 2007
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.The Journal of Experimental Medicine, 1996